RCP
SYRE icon

Remedium Capital Partners’s Spyre Therapeutics SYRE Stock Holding History

Remedium Capital Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130M Buy
1,464,169
+7,938
+0.5% +$579K 28.78% 2
2026
Q1 		$73.5M Hold
1,456,231
– – 26.13% 2
2025
Q4 		$47.7M Buy
+1,456,231
New +$38.1M 28.03% 1

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Remedium Capital Partners's SYRE Position: Q2 2026 in Review

Remedium Capital Partners increased its Spyre Therapeutics (SYRE) stake by 0.55% in Q2 2026, buying an estimated $579K and bringing the position to 1,464,169 shares worth $130M. The position accounts for 28.78% of the portfolio, ranked #2.

Remedium Capital Partners first reported a position in SYRE in Q4 2025 and has held it in 3 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Remedium Capital Partners held 1,464,169 shares of Spyre Therapeutics worth $130M as of Q2 2026.
  • Remedium Capital Partners bought 7,938 Spyre Therapeutics shares in Q2 2026, an estimated $579K.
  • Spyre Therapeutics made up 28.78% of Remedium Capital Partners's portfolio in Q2 2026, its #2 holding.
  • Remedium Capital Partners first reported a position in Spyre Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Remedium Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.